Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy

This study has been terminated.
(Caelyx was not available anymore)
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Arbeitsgemeinschaft medikamentoese Tumortherapie
ClinicalTrials.gov Identifier:
NCT00903656
First received: May 14, 2009
Last updated: December 23, 2013
Last verified: December 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: May 2012
  Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)